Physician profile
Sharon R Bradni
NPI 1902314933
$9,765.12
in general payments reported to CMS, 2019-2025
41 companies · $4,285 in 2025
The $4,285 reported for 2025 was more than what 99% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $396 · 2023: $544 · 2024: $4,296 · 2025: $4,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,896 · Travel and Lodging: $1,007 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,896.06 |
| Travel and Lodging | $1,007.25 |
| Education | $220.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,410.36 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $1,212.91 | 2024-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,088.01 | 2023-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $1,055.46 | 2022-2025 | |
| Ucb, INC. | $628.80 | 2023-2025 | Fintepla, Briviact, Nayzilam |
| Amgen INC. | $368.91 | 2024 | Repatha, Evenity |
| Acadia Pharmaceuticals INC | $301.64 | 2024-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $296.85 | 2025 | Rexulti |
| Sk Life Science, INC. | $291.38 | 2024-2025 | Xcopri |
| Pfizer INC. | $286.09 | 2023-2025 | |
| Glaxosmithkline, LLC. | $222.10 | 2022-2024 | Shingrix |
| Axsome Therapeutics, INC. | $218.23 | 2025 | Symbravo |
| Medtronic, INC. | $218.21 | 2024-2025 | Intellis Adaptivestim, Percept Pc Brainsense |
| Alexion Pharmaceuticals, INC. | $200.30 | 2024-2025 | Ultomiris |
| Saluda Medical Americas, INC. | $162.98 | 2024-2025 | Evoke |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $161.57 | 2021 | |
| Eisai INC. | $149.63 | 2024 | |
| Amneal Pharmaceuticals LLC | $147.65 | 2025 | Ongentys, Crexont |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2022 | |
| Aimmune Therapeutics, INC. | $123.63 | 2024 | |
| Dynavax Technologies Corporation | $116.64 | 2024 | Heplisav-B |
| Chiesi USA, INC. | $110.06 | 2025 | Cleviprex |
| Abiomed | $101.11 | 2025 | |
| Biogen, INC. | $97.39 | 2024-2025 | Skyclarys, Tysabri, Vumerity |
| Lundbeck LLC | $53.68 | 2024-2025 | Rexulti |
| Octapharma USA, INC. | $52.16 | 2024 | Panzyga |
| Tanabe Pharma America, INC. | $48.96 | 2024 | |
| Esperion Therapeutics, INC. | $48.75 | 2022 | |
| Neurelis, INC. | $47.68 | 2024-2025 | Valtoco |
| Csl Behring | $43.67 | 2024-2025 | Kcentra |
| Janssen Biotech, INC. | $32.80 | 2025 | |
| Globus Medical, INC. | $29.23 | 2021 | |
| Caris Mpi, INC. | $26.58 | 2025 | Mi Cancer Seek |
| Integra Lifesciences Corporation | $26.51 | 2021 | |
| Sumitomo Pharma America, INC. | $26.04 | 2024 | Aptiom |
| Averitas Pharma INC. | $25.68 | 2024 | Qutenza |
| Baxter Healthcare | $24.18 | 2023 | Hillrom - Life 2000 Ventilation System |
| Acorda Therapeutics, INC | $22.29 | 2023 | Ampyra, Inbrija |
| Ipsen Biopharmaceuticals, INC | $19.81 | 2025 | Dysport |
| Novocure INC. | $17.20 | 2025 | Optune Gio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Bradni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.